反复发作是过敏性疾病成为全球性公共卫生问题的关键所在。黄芪-防风和麻黄-甘草是减少过敏性疾病反复发作的代表性中医治则方药的二个最基本"药对"。基于TSLP（胸腺基质淋巴细胞生成素）在疾病复发时的启动开关作用和前期研究工作基础，提出：上述两"药对"对过敏性疾病的防治作用可能是通过对TSLP相关通路不同阶段的调控来实现的。本课题拟：（1）利用整体过敏性疾病模型，观察两个 "药对"对TSLP及相关通路的影响，分析其作用环节及差异性；（2）利用分子细胞技术手段，观察两个"药对"对TSLP产生、效应及调节通路的影响，揭示可能的效应靶分子；（3）利用特异性抑制剂、中和抗体干预或RNAi技术，观察两个"药对"的作用，进而反证作用靶分子。试图从TSLP这一新视角，阐明两"药对"防治过敏性疾病的关键机制，探索两对药物配伍临床不同用法和代表治则的科学内涵，为中医药防治过敏性疾病提供强有力的理论支持和实验依据。

Recurrence of allergy is a global problem of public health. Huangqi-Fangfeng and Mahuang-Gancao, utilized in different phase, are basic combinations in effective formula for relapse prevention of allergy. TSLP (thymic stromal lymphopoietin) has been proven to be a master switch of the initiation of type 2 immunity recently. Based on our previous study, we propose that the effects of Huangqi-Fangfeng and Mahuang-Gancao combination on allergy might be related with different regulation of TSLP -related pathways. In this study, the following research would be conducted: (1) Effect of Huangqi-Fangfeng and Mahuang-Gancao combination on allergy and TSLP-related pathway would be carried out on mouse model; (2) Effect of Huangqi-Fangfeng and Mahuang-Gancao combination on production, influence and regulation of TSLP would be investigated in vitro; (3) Main targets of Huangqi-Fangfeng and Mahuang-Gancao combination would be confirmed by employing specific inhibitors, antibodies or RNAi. Through this study, mechanism of Huangqi-Fangfeng and Mahuang-Gancao combination on allergic disease and their differences might be illustrated and further theoretical and experimental evidence could be provided for clinic application.